European Thyroid Journal

Home
United Kingdom
Bristol
European Thyroid Journal

The official journal of the European Thyroid Association, publishing basic, translational and clinical thyroidology.

The European Thyroid Journal publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.

22/12/2025

A new review by Luigi Bartalena et al. compares the European Group on Graves’ orbitopathy (EUGOGO) 2021 guidelines and the American and European Thyroid Associations’ (ATA/ETA) 2022 consensus statement on the management of Graves’ orbitopathy (GO).

They found strong concordance on classification, assessment, prevention, and treatment of mild GO, moderate‑to‑severe and inactive GO, and sight‑threatening GO. The main divergence between the documents lies in guidance for the management of moderate‑to‑severe and active GO.

The review also provides considered revisions to current recommendations, incorporating the most recent additions to the literature.

📖 Read the full article: https://doi.org/10.1530/ETJ-25-0318

16/12/2025

💙 Uniting for thyroid health in Africa

After the International Round Table - Global Challenges in Thyroid Health at the International Thyroid Congress, an editorial calls for collaboration among continental thyroid societies to strengthen clinical practice & advocacy.

doi.org/10.1530/ETJ-25-0374

08/12/2025

New cryo-EM studies provide detailed structural insights into the full-length human TSH receptor (TSHR) and its interactions with monoclonal autoantibodies.

A review by Bernard Rees Smith, Ricardo Núñez Miguel, and Jane Sanders offers key highlights:
• Stimulating antibodies (M22™, K1-18™) bind the entire LRD (LRR 1–11) concave surface, stabilising the receptor in its active state.
• Blocking type monoclonal antibody (K1-70™) binds LRR 1–7, preventing TSH and other TRAb from interacting.
• 5C9™ interacts differently, locking the receptor in the inactive state, inhibiting constitutive and mutation-driven activity.

👉 Read the full article: doi.org/10.1530/ETJ-25-0261

02/12/2025

💫 Prof. Marek Niedziela is a leading expert in paediatric thyroid diseases, with a focus on nodular disease (genetically determined multinodular goiter - DICER1 syndrome, hot nodules and thyroid cancer) and autoimmune thyroid disorders. As Head of Paediatric Endocrinology and Rheumatology at PUMS, he has advanced both clinical care and research for over two decades.

We are delighted to have his expertise on the European Thyroid Journal Editorial Board and as Collection Editor for our new Special Collection: Current Approaches and Challenging Issues in Paediatric Thyroid Carcinoma.

📢 This is a unique opportunity to amplify your work and contribute to the future of paediatric thyroidology.

👉 More info: etj.bioscientifica.com/page/paediatric-thyroid-carcinoma%20/current-approaches-and-challenging-issues-in-paediatric-thyroid-carcinoma

25/11/2025

Resistance to thyroid hormone β (RTHβ) is characterised by elevated thyroid hormone concentrations with non‑suppressed thyroid‑stimulating hormone (TSH) levels, and shows considerable phenotypic variability. Mosaic mutations causing mild RTHβ are extremely rare, with only three cases reported to date.

A new case report by Ferdy S. van Geest et al. describes a novel eight‑base‑pair duplication in THRB (c.1305_1312dup; (p.R438Lfs445X)) occurring in a mosaic pattern, resulting in a distinctive and severe developmental and thyrotoxic phenotype.

This report underscores the importance of recognising mosaicism in RTHβ diagnosis and demonstrates the beneficial effects of combined methimazole/Triac therapy in severe RTHβ, with potential implications for clinical management.

📖 Read the full article here: https://doi.org/10.1530/ETJ-25-0092

18/11/2025

🧬Discover the emerging roles of DICER1 and DGCR8 in thyroid tumorigenesis and their impact on miRNA biogenesis and histopathologic diversity.

Our latest open-access review by Lia Rodrigues synthesises the latest evidence on:
- Germline and somatic mutations in DICER1 and DGCR8
- Links to thyroid pathology and oncolytic morphology
- Clinical implications for diagnosis, genetic counselling, and patient management
- Future directions for refining surveillance and therapeutic approaches

📖 Read the full article here: doi.org/10.1530/ETJ-25-0188

11/11/2025

📢 Call for Papers: Paediatric Thyroid Carcinoma – Current Approaches & Challenges

Our latest special collection is led by international experts in the fields of paediatrics and endocrinology with a specialised interest in paediatric thyroid cancer:
- Professor Marek Niedziela
- Professor Hanneke van Santen
- Professor Andy Bauer

This collection will feature a series of review articles on current approaches and ongoing challenges in the evaluation and treatment of thyroid carcinoma. Topics will include the new WHO classification of thyroid tumours and the paediatric Bethesda system for reporting thyroid cytopathology, alongside reviews of imaging, surgical, and non-surgical treatment modalities. We will explore the risks and benefits associated with each aspect of care.

📝 If you specialise in paediatric thyroid carcinoma, this is a valuable opportunity to contribute to a dedicated and expert-led collection. We welcome literature reviews on all aspects of paediatric thyroid carcinoma.

📧 Submit your proposal: etj@bioscientifica.com
💻 https://etj.bioscientifica.com/page/paediatric-thyroid-carcinoma%20/current-approaches-and-challenging-issues-in-paediatric-thyroid-carcinoma

05/11/2025

Thyroid cancer is the most common endocrine malignancy and its tumors show striking genotype-phenotype correlations.

A new review by Giulia Calafato et al. provides a comprehensive, up-to-date summary of the somatic genetic and molecular alterations that drive development and progression of thyroid tumors of follicular cell origin.

Understanding the genetic landscape and related molecular mechanisms is essential to refine clinical management and to identify targeted therapies for aggressive and advanced forms of carcinoma.

Read the full review: doi.org/10.1530/ETJ-25-0104

28/10/2025

🌐 Thyrotoxic periodic paralysis (TPP) is a rare but potentially life-threatening complication of thyrotoxicosis. Due to its rarity, it poses considerable challenges when initiating epidemiological studies.

New research by Gloria Hoi-Yee Li introduces a novel algorithm and electronic medical database from Hong Kong to establish the first large-scale registry of TPP. The data reveal a steady rise in thyrotoxicosis incidence, while TPP remains rare, male-dominant, and clinically stable in terms of hospitalization and length of stay.

This registry offers a new lens for understanding the epidemiology of TPP and enables future studies focused on identifying precipitating factors to improve management strategies for this complication.

📖 Read the research: doi.org/10.1530/ETJ-25-0220

21/10/2025

Could a more systematic search for NUTM1 fusions improve the identification of poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer?

A new case report by Renaud Ciappuccini et al. describes two patients over 65 with PDTC harbouring the NSD3::NUTM1 translocation - a fusion typically seen in younger patients and only rarely reported in primary thyroid cancer.

These findings support the inclusion of NUTM1 fusions in RNA sequencing panels for advanced and refractory thyroid cancers, with potential implications for diagnosis and treatment strategies.

🔗 Read the article: doi.org/10.1530/ETJ-25-0100

16/10/2025

Thyroid cancer with laryngotracheal invasion can lead to life‑threatening airway stenosis, often necessitating urgent and invasive procedures such as tracheostomy, stenting or extensive surgery.

New research by Hiroshi Katoh et al. investigates lenvatinib (LEN) as an initial and bridging therapy, showing its potential to rapidly relieve airway obstruction and to serve as a valuable option during the genetic testing period in anaplastic thyroid cancer (ATC).

✨ These findings position LEN as a promising non‑invasive alternative to emergency interventions and an important therapeutic bridge for patients with ATC.

📖 Read the full study: doi.org/10.1530/ETJ-25-0212

15/10/2025

Exciting news! Our publisher, Bioscientifica, is partnering with Silverchair to deliver an enhanced online experience for our readers, authors and the wider scientific community.

This strategic partnership will bring our entire publishing portfolio, including European Thyroid Journal, to the Silverchair Platform - offering an improved user experience, increased discoverability and business intelligence to support our mission and future growth.

🔗 Read more about the partnership: www.silverchair.com/news/silverchair-partners-with-bioscientifica/

Address

Bristol

Website

https://etj.bioscientifica.com/

Alerts

Be the first to know and let us send you an email when European Thyroid Journal posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to European Thyroid Journal:

Shortcuts

Featured

Sylvian Care South Gloucestershire
Equinox South, Great Park Road, Bradley Stoke, BS32 4QL

Want your practice to be the top-listed Clinic in Bristol?